ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial

ALX Oncology has revealed topline data from its Phase II ASPEN-06 clinical trial, indicating that evorpacept, in combination with standard therapies, enhanced tumour response in patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer.